Viking Therapeutics is a challenger in the obesity drugs gold rush, trailing Eli Lilly and Novo Nordisk as they rake in cash from their highly successful medicines.
VIKING THERAPEUTICSELI LILLYNOVO NORDISKVIGIVIKING
Statements (5)
- Bullish
Viking Therapeutics is likely to continue its strong performance as GLP-1 maintenance data outperforms major obesity peers, suggesting the catalyst may be unique to Viking.
- Bullish
Viking Therapeutics is likely to see its stock price rise as it develops VK2735, a GLP-1/GIP drug that could compete with Eli Lilly's Zepbound.
- Neutral
Viking Therapeutics shares are likely to surge while Eli Lilly and Novo shares are likely to fall due to positive obesity drug data reports.
- Bullish
Viking Therapeutics reported positive data on its obesity drug, causing stock to surge.
- Neutral
Viking Therapeutics' obesity drug shows 22% weight loss in study